1994
Increased Systemic, but Not Regional, Neopterin Production Following Intraperitoneral Administration of Interleukin-2 and Lack of Effect of Pterins upon the Lymphokine-Activated Killer Cell Phenomenon
Roberts J, Bigelow J, Moore A, Belinson J, Stewart J, Hacker M. Increased Systemic, but Not Regional, Neopterin Production Following Intraperitoneral Administration of Interleukin-2 and Lack of Effect of Pterins upon the Lymphokine-Activated Killer Cell Phenomenon. Journal Of Immunotherapy 1994, 15: 53-58. PMID: 8110731, DOI: 10.1097/00002371-199401000-00007.Peer-Reviewed Original ResearchConceptsLymphokine-activated killer cellsNeopterin productionInterleukin-2Killer cellsIntraperitoneal interleukin-2Killer cell phenomenonUrinary neopterin excretionRoute of administrationActivated T cellsPresence of neopterinNumber of cytokinesLack of effectN-acetyl serotoninIncreased SystemicNeopterin excretionOvarian carcinomaT cellsImmune responseClinical administrationNeopterinCytotoxic effectsAdministrationSynthesis inhibitorCell phenomenonCells
1990
Phase I trial of intraperitoneal recombinant interleukin-2/lymphokine-activated killer cells in patients with ovarian cancer.
Stewart JA, Belinson JL, Moore AL, Dorighi JA, Grant BW, Haugh LD, Roberts JD, Albertini RJ, Branda RF. Phase I trial of intraperitoneal recombinant interleukin-2/lymphokine-activated killer cells in patients with ovarian cancer. Cancer Research 1990, 50: 6302-10. PMID: 2205379.Peer-Reviewed Original ResearchConceptsLymphokine-activated killer cellsRecombinant interleukin-2LAK activityIL-2Killer cellsDose levelsMononuclear cellsUnits/m2 body surface areaIntraperitoneal recombinant interleukin-2M2 body surface areaLAK/ILOvarian cancer refractorySerum IL-2Less IL-2Dose-limiting toxicityPhase I trialIL-2 levelsAdditional IL-2IL-2-dependent cell lineBody surface areaSignificant weight gainMononuclear cell collectionPeripheral blood cellsHighest dose levelCancer refractory